Literature DB >> 17699779

Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis.

Aejaz Sayeed1, Santhi D Konduri, Wensheng Liu, Sanjay Bansal, Fengzhi Li, Gokul M Das.   

Abstract

Estrogen receptor alpha (ERalpha) and tumor suppressor protein p53 exert opposing effects on cellular proliferation. As a transcriptional regulator, p53 is capable of activating or repressing various target genes. We have previously reported that ERalpha binds directly to p53, leading to down-regulation of transcriptional activation by p53. In addition to transcriptional activation, transcriptional repression of a subset of target genes by p53 plays important roles in diverse biological processes, such as apoptosis. Here, we report that ERalpha inhibits p53-mediated transcriptional repression. Chromatin immunoprecipitation assays reveal that ERalpha interacts in vivo with p53 bound to promoters of Survivin and multidrug resistance gene 1, both targets for transcriptional repression by p53. ERalpha binding to p53 leads to inhibition of p53-mediated transcriptional regulation of these genes in human cancer cells. Transcriptional derepression of Survivin by ERalpha is dependent on the p53-binding site on the Survivin promoter, consistent with our observation that p53 is necessary for ERalpha to access the promoters. Importantly, mutagenic conversion of this site to an activation element enabled ERalpha to repress p53-mediated transcriptional activation. Further, RNA interference-mediated knockdown of ERalpha resulted in reduced Survivin expression and enhanced the propensity of MCF-7 cells to undergo apoptosis in response to staurosporine treatment, an effect that was blocked by exogenous expression of Survivin. These results unravel a novel mechanism by which ERalpha opposes p53-mediated apoptosis in breast cancer cells. The findings could have translational implications in developing new therapeutic and prevention strategies against breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699779     DOI: 10.1158/0008-5472.CAN-06-3724

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  72 in total

1.  Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Cε.

Authors:  Moammir H Aziz; Hong Shen; Carl G Maki
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

Review 2.  Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication.

Authors:  Nadi T Wickramasekera; Gokul M Das
Journal:  Mitochondrion       Date:  2013-10-29       Impact factor: 4.160

3.  Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

Authors:  George C Bobustuc; Cheryl H Baker; Arati Limaye; Wayne D Jenkins; Gary Pearl; Nicholas G Avgeropoulos; Santhi D Konduri
Journal:  Neuro Oncol       Date:  2010-06-04       Impact factor: 12.300

Review 4.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

5.  Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin.

Authors:  Xiang Ling; Xiang He; Pasha Apontes; Felicia Cao; Rami G Azrak; Fengzhi Li
Journal:  Am J Transl Res       Date:  2009-07-15       Impact factor: 4.060

6.  Potential interference of aluminum chlorohydrate with estrogen receptor signaling in breast cancer cells.

Authors:  Vyron A Gorgogietas; Ioannis Tsialtas; Natalie Sotiriou; Vasiliki C Laschou; Aikaterini G Karra; Demetres D Leonidas; George P Chrousos; Evagelia Protopapa; Anna-Maria G Psarra
Journal:  J Mol Biochem       Date:  2018

7.  Estrogen receptor prevents p53-dependent apoptosis in breast cancer.

Authors:  Shannon T Bailey; Hyunjin Shin; Thomas Westerling; Xiaole Shirley Liu; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-17       Impact factor: 11.205

8.  Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.

Authors:  Ying Jin; Wenquan Hu; Tong Liu; Ujala Rana; Irene Aguilera-Barrantes; Amanda Kong; Suresh N Kumar; Bei Wang; Pin Gao; Xiang Wang; Yajun Duan; Aiping Shi; Dong Song; Ming Yang; Sijie Li; Bing Han; Gang Zhao; Zhimin Fan; Qing Robert Miao
Journal:  Cancer Lett       Date:  2018-02-02       Impact factor: 8.679

9.  Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells.

Authors:  Stephanie Harkey Shirley; Joyce E Rundhaug; Jie Tian; Noirin Cullinan-Ammann; Isabel Lambertz; Claudio J Conti; Robin Fuchs-Young
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.

Authors:  Xiang Ling; Diane Calinski; Asher A Chanan-Khan; Muxiang Zhou; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2010-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.